

We claim:

1. A method for the treatment of renal disorders comprising administering to mammal a therapeutically effective amount of standardized extract of *Tinospora cordifolia* as an immunoadjuvant, in conjunction with conventional therapy.
2. The method of claim 1, wherein the renal disorders are nephrotic syndrome and chronic recurrent urinary tract infections, both complicated and uncomplicated
3. The method of claim 2, wherein the chronic recurrent urinary tract infection is due to relapsing bacterial infection.
4. The method of claim 3, wherein the chronic recurrent urinary tract infection is due to relapsing *E. coli* and *Klebsiella* infections.
5. The method of claim 2, wherein nephrotic syndrome occurs due to a variety of kidney diseases caused by primary glomerulonephritis.
6. The method of claim 5, wherein kidney diseases caused by primary glomerulonephritis are Membranoproliferative Glomerulonephritis/Mesangiocapillary Glomerulonephritis (MPGN), Focal segmental glomerulosclerosis (FSGS), Focalproliferative Glomerulonephritis (FPGN) and Minimal change nephrotic syndrome (MCNS).

7. The method of claim 1, wherein the standardized extract of *Tinospora cordifolia* acts as an immunoadjuvant in the treatment of chronic recurrent urinary tract infections, in conjunction with conventional antibacterial therapy.
- 5 8. The method of claim 1, wherein the conventional therapy for recurrent urinary tract infections includes the use of at least one antibacterial agent selected from ciprofloxacin, ofloxacin, norfloxacin, trimethoprim-sulfamethoxazole, amoxicillin, nitrofurantoin, ampicillin and lomefloxacin.
- 10 9. The method of claim 1, wherein the standardized extract of *Tinospora cordifolia* acts as an immunoadjuvant in reducing relapses of nephrotic syndrome, in conjunction with conventional steroidal therapy.
- 15 10. The method of claim 9, wherein the standardized extract of *Tinospora cordifolia* reduces the side effects of conventional steroid therapy and reduces relapse rates.
11. The method of claim 9, wherein the steroids are selected from the group consisting of prednisolone and methyl prednisolone.
- 20 12. The method of claim 1, wherein the extract of *Tinospora cordifolia* is standardized by bioassay.
13. The method of claim 12, wherein the bioassay comprises evaluating bioactivity by determining the percentage of phagocytosis over a base value, wherein the percentage
25 of phagocytosis is not less than 30% over a base value.
14. A pharmaceutical composition, comprising a therapeutically effective amount of standardized extract of *Tinospora cordifolia* and a pharmaceutically acceptable carrier.

15. A method for the treatment of renal disorders in a mammal, comprising administering to said mammal a therapeutically effective amount of the pharmaceutical composition of claim 14.
- 5 16. A pharmaceutical composition, comprising a therapeutically effective amount of standardized extract of *Tinospora cordifolia* in combination with at least one other herbal constituent.
- 10 17. A method of improving the effectiveness of an agent for treating renal disorders, comprising administering an effective amount of standardized extract of *Tinospora cordifolia* to a mammal undergoing treatment with the agent for treating renal disorders.